# Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial

Study · id `cardio:ct-nct02699645` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02699645](<https://clinicaltrials.gov/study/NCT02699645>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02699645

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: High blood pressure; Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1671 participants.

## Technical summary

Registry record NCT02699645. Randomized; quadruple masking; primary purpose prevention. Start 2017-09-28 (actual); primary completion 2025-08-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 1671 participants (enrolled count; ClinicalTrials.gov record NCT02699645, source copy `cardio:ctgov-nct02699645-2025-09-12`, retrieved 2026-10-26)
- Started: 2017-09-28 (actual) (ClinicalTrials.gov record NCT02699645, source copy `cardio:ctgov-nct02699645-2025-09-12`, retrieved 2026-10-26)
- Primary completion: 2025-08-27 (actual) (ClinicalTrials.gov record NCT02699645, source copy `cardio:ctgov-nct02699645-2025-09-12`, retrieved 2026-10-26)
- Completion: 2025-08-27 (actual) (ClinicalTrials.gov record NCT02699645, source copy `cardio:ctgov-nct02699645-2025-09-12`, retrieved 2026-10-26)
- Countries: Australia; Brazil; Georgia; Malaysia; Netherlands; Nigeria; Singapore; Sri Lanka; Taiwan; United Kingdom (ClinicalTrials.gov record NCT02699645, source copy `cardio:ctgov-nct02699645-2025-09-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02699645-2025-09-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial
- Acronym: TRIDENT
- Condition: Intracerebral Haemorrhage (ICH)
- Condition: Hypertension
- Intervention (Drug): telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg
- Intervention (Drug): Placebo
- Lead sponsor: The George Institute
- Lead sponsor class: OTHER
- Collaborator: The University of New South Wales
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: The George Institute for Global Health (`core:george-institute`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage (`cardio:pubmed-42019018`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 506dc0d1c58581d857867ed4e4d167f81b6518c3eb6d20de9c9625ce53ee4bef
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
